Acute hepatic porphyrias (AHP) are rare, inherited disorders of heme biosynthesis that cause life-threatening neurovisceral attacks. The four subtypes are acute intermittent porphyria (AIP) (most common, ~1 in 100,000), variegate porphyria (VP), hereditary coproporphyria (HCP), and ALA dehydratase deficiency porphyria (ALAD). Attacks predominantly affect women of reproductive age (80–90% of cases) and are frequently misdiagnosed due to nonspecific symptoms mimicking common surgical and psychiatric conditions. [1-2]
The following figure illustrates the heme biosynthetic pathway and the enzymatic defects responsible for each porphyria subtype:
1. History
- Key HPI: Severe, diffuse abdominal pain (present in ~90% of attacks) — often described as colicky, poorly localized, without peritoneal signs. Pain may radiate to back or thighs. [2-3]
- Timing/triggers: Ask about recent medication changes (especially CYP450 inducers), fasting/crash diets, bariatric surgery, menstrual cycle timing (catamenial attacks in luteal phase), alcohol use, smoking, infections, and psychological stress. [1-2]
- Progression: Prodrome of fatigue, inability to concentrate, and insomnia for days before pain onset. Attacks typically last 1–2 weeks. [2][4]
- Associated symptoms: Nausea, vomiting, constipation, dark/reddish urine, limb pain, weakness, anxiety, confusion, hallucinations, seizures. [2][4]
- Important negatives: Absence of rebound tenderness, guarding, or peritoneal signs despite severe pain. Normal abdominal imaging despite severe symptoms — this discordance is a key diagnostic clue. [2][5]
2. Alarm Features
- Seizures (~20% of acute attacks) — may be due to hyponatremia, hypomagnesemia, or direct neurotoxicity [1-2]
- Progressive motor neuropathy — proximal > distal, arms > legs; can progress to quadriplegia and respiratory paralysis [4]
- Severe hyponatremia (SIADH in ~40% of attacks) — risk of precipitous drop with hypotonic fluids [2][4]
- Posterior reversible encephalopathy syndrome (PRES) on MRI [6-7]
- Bulbar paralysis / respiratory failure — requires ICU and mechanical ventilation [4]
- "Purple flag" triad: Seizures + abdominal pain + hyponatremia in a young woman is highly suggestive [2][5]
3. Medications
Contraindicated / Porphyrinogenic (induce CYP450 / ALAS1)
- Barbiturates, phenytoin, carbamazepine, valproic acid
- Sulfonamide antibiotics, griseofulvin, rifampin
- Oral contraceptives (progesterone-containing), progestins
- Ergot alkaloids, metoclopramide
- Alcohol [1][8]
Safe medications during attacks
- Analgesics: Opioids (morphine, fentanyl), acetaminophen
- Antiemetics: Ondansetron, phenothiazines (chlorpromazine — also useful for agitation)
- Antiseizure: Magnesium sulfate, benzodiazepines, levetiracetam
- Antihypertensives: Beta-blockers (if needed)
- Specific therapy: IV hemin (Panhematin), IV dextrose [1-2][4]
Prophylactic therapy for recurrent attacks (≥4/year)
- Givosiran (Givlaari) — subcutaneous siRNA targeting ALAS1 mRNA, FDA-approved for adults with AHP [1][9]
- Prophylactic IV hemin infusions [1][3]
Drug safety databases: porphyria.org and drugs-porphyria.org should be consulted before prescribing any medication. [1][3]
4. Diet
- Caloric deprivation is a major trigger — fasting, crash diets, and bariatric surgery can precipitate attacks by upregulating ALAS1 via PGC-1α [1-2]
- Carbohydrate loading is therapeutic: oral high-carbohydrate diet for mild attacks; IV 10% dextrose in 0.45% saline (~300 g/day glucose) for moderate-severe attacks [1-3]
- Avoid hypotonic dextrose in water — worsens hyponatremia [3-4]
- Long-term: Maintain adequate caloric intake; >50% of energy from carbohydrates. Avoid prolonged fasting [3]
5. Review of Systems
- GI: Abdominal pain, nausea, vomiting, constipation (ileus), weight loss in prolonged attacks
- Neuro: Weakness (proximal > distal), paresthesias, dysesthesias, seizures, altered mental status, confusion
- Psych: Anxiety, depression, hallucinations, paranoia, disorientation (20–30% of patients) [4]
- Autonomic: Tachycardia, hypertension, diaphoresis, urinary retention
- Skin: Photosensitive blistering lesions on sun-exposed areas (VP and HCP only — not AIP) [7]
- Urine: Dark, reddish-brown, or tea-colored urine (may only darken on standing) [2][6]
6. Collateral History and Family History
- Family history: Autosomal dominant inheritance with low penetrance — most carriers are asymptomatic; absence of family history does not exclude diagnosis [3]
- Ask about family members with unexplained abdominal pain, psychiatric symptoms, or neuropathy
- Genetic counseling and cascade testing of at-risk relatives recommended after index case confirmed [1][3]
- Social context: Assess for alcohol use, smoking, dietary habits, stress levels, and recent infections [1]
7. Risk Factors
- Female sex — 80–90% of symptomatic patients are women of reproductive age [2]
- Hormonal fluctuations — progesterone surge (luteal phase), oral contraceptives, pregnancy [1-2]
- Porphyrinogenic medications — CYP450 inducers [1]
- Caloric deprivation — fasting, crash diets, bariatric surgery [2]
- Alcohol and tobacco use [1][3]
- Acute illness / infection / surgery [1][7]
- Psychological stress [1]
8. Differential Diagnosis
- Acute surgical abdomen (appendicitis, cholecystitis, bowel obstruction) — distinguished by peritoneal signs, imaging findings
- Guillain-Barré syndrome — ascending weakness, elevated CSF protein (normal in AIP), normal urine PBG [3]
- Lead poisoning — abdominal pain + elevated urine ALA, but normal PBG; anemia present (not typical of AIP) [2-3]
- Tyrosinemia type 1 — elevated ALA without PBG elevation [2-3]
- Functional abdominal pain / drug-seeking behavior — frequently misdiagnosed due to benign exam and poor opioid response [2]
- Addisonian crisis — hyponatremia, abdominal pain, hypotension
- Other AHP subtypes (VP, HCP) — clinically indistinguishable neurovisceral attacks; differentiated by urine/stool porphyrin profiles and genetics [3]
9. Past Medical History
- Prior episodes of unexplained abdominal pain, especially with negative surgical workups
- Previous ED visits with nondiagnostic evaluations — a hallmark pattern [2]
- History of psychiatric diagnoses (anxiety, depression, psychosis)
- Prior surgeries (especially if attacks were perioperative)
- Chronic complications of AHP: Hypertension, chronic kidney disease, chronic liver disease, hepatocellular carcinoma (even without cirrhosis) [1]
10. Physical Exam
Vital signs
- Tachycardiahypertension[1-2]
Abdominal exam
- Unexpectedly benign despite severe pain — no rebound, no guarding, no rigidity [2]
- Mild distension or decreased bowel sounds (ileus) may be present
Neurologic exam
- Proximal muscle weakness (arms > legs)
- Decreased or absent deep tendon reflexes
- Sensory changes (dysesthesias, paresthesias)
- Mental status changes (confusion, agitation, hallucinations)
- Check respiratory effort — intercostal weakness may herald respiratory failure [4]
Skin
Urine
11. Lab Studies
Diagnostic
- Random urine PBG and ALA (normalized to creatinine) — the screening test of choice. During attacks, PBG is elevated ≥5-fold (often 10–150× upper limit of normal). A 24-hour collection is NOT required [1-2]
- Urine porphyrins — helpful for subtyping but should NOT be used alone as a screening test (secondary porphyrinurias cause false positives) [1]
Supportive labs
- BMP: Hyponatremia (~40%), hypomagnesemia [1-2]
- LFTs: Mild transaminase elevation [2]
- CBC: Usually normal (anemia suggests lead poisoning, not AIP) [3]
- Renal function: Baseline and monitoring (CKD is a long-term complication) [1]
Confirmatory
Monitoring on treatment
- On hemin: Iron studies, ferritin [1]
- On givosiran: CMP, homocysteine, urinalysis, protein/creatinine ratio, B12/folate, amylase/lipase [1]
12. Imaging
- Abdominal CT/ultrasound: Typically normal or shows nonspecific ileus — this is a key diagnostic clue. Imaging is primarily useful to exclude surgical pathology [1-2]
- Brain MRI: May show posterior reversible encephalopathy syndrome (PRES) in severe attacks with encephalopathy/seizures [4][6-7]
- Liver ultrasound: Recommended annually for long-term surveillance for hepatocellular carcinoma (beginning at age 50 or after prolonged biochemical activity) [1][8]
- Imaging is generally not diagnostic of AHP itself — diagnosis is biochemical
13. Special Tests
- Watson-Schwartz / Hoesch test: Rapid qualitative bedside urine PBG test — historically useful but limited availability; a newer rapid PBG test (Teco Diagnostics) has been approved in the US [1-2]
- Plasma fluorescence emission scanning at 626 nm — useful for differentiating VP from other AHP subtypes
- Stool porphyrins — elevated coproporphyrin III in HCP; elevated protoporphyrin and coproporphyrin in VP
- Erythrocyte PBG deaminase activity — reduced in ~90% of AIP patients but not reliable as sole diagnostic test [3]
- EMG/NCS: Axonal motor neuropathy pattern if peripheral neuropathy present [6]
- Genetic testing — definitive for subtype classification and family screening [1]
14. ECG
- Sinus tachycardia — most common finding, reflecting autonomic dysfunction [1-2]
- ECG primarily useful to rule out cardiac causes of chest/abdominal pain
- No pathognomonic ECG pattern for AHP
- Monitor for electrolyte-related changes (hyponatremia, hypomagnesemia → QT prolongation, arrhythmia risk)
15. Assessment
Severity stratification
- Mild attack: Pain manageable without opioids, no hyponatremia, no seizures, no motor weakness → may consider outpatient management with oral carbohydrate loading [8][10]
- Moderate-severe attack: Requires opioids, or presence of hyponatremia, seizures, or motor neuropathy → hospital admission and IV hemin [1][10]
- Life-threatening attack: Respiratory compromise, bulbar paralysis, severe encephalopathy, status epilepticus → ICU admission [4][8]
Typical presentation: Young woman with recurrent severe abdominal pain, tachycardia, hypertension, benign abdominal exam, hyponatremia, and prior nondiagnostic ED evaluations. [2]
Complications: Motor neuropathy (potentially irreversible if treatment delayed), respiratory failure, PRES, chronic pain syndrome, CKD, hypertension, HCC. [1][4]
16. Treatment Plan
Initial stabilization
- Discontinue all porphyrinogenic medications immediately [1-2]
- IV fluids: 10% dextrose in 0.45% saline — avoid hypotonic dextrose in water [2][4]
- Aggressive pain control with opioids (morphine, fentanyl)
- Antiemetics: ondansetron; chlorpromazine for agitation/anxiety [4][8]
- Monitor and correct electrolytes: slow correction of hyponatremia; IV magnesium sulfate [1]
Specific therapy
- IV hemin (Panhematin): 3–4 mg/kg/day IV over 30–40 min, once daily for 3–5 days. Administer via large peripheral vein or central line (PICC preferred). Reconstitute with human serum albumin for stability. Do not exceed 6 mg/kg in 24 hours [1-2][11]
- Collect random urine for ALA/PBG/creatinine before starting hemin [1]
- Clinical response (pain/nausea resolution) typically by day 4; PBG decrease by day 3 [2]
- IV glucose alone (300–400 g/day) is appropriate only for mild attacks or as a bridge until hemin is available [1][10-11]
Seizure management
- Safe options: Magnesium sulfate, benzodiazepines (lorazepam), levetiracetam [1]
- Avoid: Barbiturates, phenytoin, carbamazepine, valproic acid [1]
Prophylaxis for recurrent attacks (≥4/year)
- Givosiran (Givlaari) 2.5 mg/kg SC monthly — siRNA targeting hepatic ALAS1 [1][3][9]
- Prophylactic IV hemin infusions (weekly or biweekly) [3]
- GnRH agonists for catamenial attacks [3]
- Liver transplantation — curative, reserved for intractable cases failing all other therapies [1][3]
17. Disposition
Admit if
- Pain requiring opioid analgesia
- Hyponatremia, seizures, or motor weakness
- Need for IV hemin therapy
- Inability to maintain oral intake [8][10]
ICU admission if
- Seizures, bulbar signs, respiratory compromise
- Severe hypertensive crisis / PRES
- Progressive motor neuropathy with declining vital capacity [4][8]
Discharge criteria
- Pain controlled without opioids
- Adequate oral caloric intake
- Stable electrolytes
- No progressive neurologic deficits [2]
Specialist consultation
- Porphyria specialist / hepatologist (American Porphyria Foundation maintains a specialist directory)
- Neurology if motor neuropathy or seizures
- Genetics for confirmatory testing and family screening [1-2]
18. Follow Up / Return Precautions
Follow-up timing
- Porphyria specialist within 1–2 weeks of discharge
- Annual monitoring: LFTs, creatinine/eGFR, liver ultrasound (HCC screening), blood pressure [1]
- Genetic counseling and cascade family testing [1][3]
Return precautions — instruct patients to seek immediate care for:
- Recurrence of severe abdominal pain
- New weakness in arms or legs
- Seizures or confusion
- Dark or red urine
- Inability to eat or drink
Patient counseling
- Carry a medical alert card/bracelet identifying AHP diagnosis
- Consult drug safety databases before starting any new medication (porphyria.org)
- Avoid fasting, crash diets, alcohol, smoking
- Maintain adequate carbohydrate intake during illness
- Inform all healthcare providers of diagnosis, especially before surgery or anesthesia [1][3]
Expected recovery: Most uncomplicated attacks resolve within 1–2 weeks with appropriate treatment. Motor neuropathy recovery is gradual and may be incomplete. Hemin therapy is not effective in reversing established neuronal damage — early treatment is critical. [2][4][11]
References
1. AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review. — Wang B, Bonkovsky HL, Lim JK, Balwani M. Gastroenterology. 2023.
2. Porphyria. — Bissell DM, Anderson KE, Bonkovsky HL. The New England Journal of Medicine. 2017.
3. Acute Intermittent Porphyria. — Sardh E, Barbaro M GeneReviews® [Internet]. 2024.
4. Porphyrias. — Puy H, Gouya L, Deybach JC. Lancet. 2010.
5. Acute Hepatic Porphyrias: "Purple Flags"-Clinical Features That Should Prompt Specific Diagnostic Testing. — Anderson KE, Desnick RJ, Stewart MF, Ventura P, Bonkovsky HL. The American Journal of the Medical Sciences. 2022.
6. An Easily Overlooked Disease in the Early Stages: Acute Intermittent Porphyria. — Wang J, Chen J, Xu K, et al. BMC Neurology. 2025.
7. Update on the Diagnosis and Management of the Autosomal Dominant Acute Hepatic Porphyrias. — Schulenburg-Brand D, Stewart F, Stein P, Rees D, Badminton M. Journal of Clinical Pathology. 2022.
8. Variegate Porphyria. — Singal AK, Anderson KE GeneReviews® [Internet]. 2019.
9. FDA Orange Book. — FDA Orange Book. 2026.
10. Recommendations for the Diagnosis and Treatment of the Acute Porphyrias. — Anderson KE, Bloomer JR, Bonkovsky HL, et al. Annals of Internal Medicine. 2005.
11. FDA Drug Label. — Updated date: 2026-02-26. Food and Drug Administration.